Drug Profile


Alternative Names: K 877

Latest Information Update: 09 Jan 2017

Price : $50

At a glance

  • Originator Kowa Pharmaceutical
  • Class Antihyperlipidaemics
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Dyslipidaemias
  • Phase III Hypertriglyceridaemia

Most Recent Events

  • 03 Jan 2017 Phase-III clinical trials in Dyslipidaemias in European Union (PO)
  • 03 Jan 2017 Phase-III clinical trials in Dyslipidaemias in USA (PO)
  • 01 Nov 2016 Kowa Research Institute initiates a phase III trial for Hypertriglyceridaemia in USA (PO) (NCT03011450)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top